AssayQuant

Executive Summary

AssayQuant is a Cambridge-based biotechnology company specializing in real-time enzyme activity assays and profiling services for drug discovery. Its proprietary PhosphoSens® technology enables continuous, kinetic measurement of kinase and phosphatase activities, providing deeper mechanistic insights compared to traditional endpoint assays. This platform is particularly valuable in oncology and inflammatory disease research, where kinase dysregulation is common. The company serves both diagnostics and proteomics sectors, offering assay kits and KinSight™ profiling services that accelerate preclinical drug development. By enabling researchers to observe enzyme kinetics in real time, AssayQuant reduces time to data and enhances the predictive power of early-stage studies. Founded in 2010, the company is currently in the pre-clinical stage and privately held. Its technology has the potential to become a standard tool in drug discovery, especially as the industry shifts toward more dynamic biochemical characterization. AssayQuant's focus on kinase and phosphatase profiling positions it well within the growing targeted therapy market. While the company has not disclosed financials or major partnerships publicly, its niche expertise and established presence in Cambridge suggest a promising trajectory. Continued investment in platform expansion and strategic collaborations will be key to capturing market share in the competitive assay services landscape.

Upcoming Catalysts (preview)

• Q3 2026Launch of expanded PhosphoSens assay kits for new kinase targets75% success
• Q4 2026Strategic partnership with a top-20 pharmaceutical company for kinase profiling60% success
• Q1 2027Series A funding round to scale commercial operations70% success